TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01892345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
Study: NCT01488708
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Study: NCT01488708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
Study: NCT03427554
Drug: Tretinoin cream 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
Study: NCT03427554
Drug: RETIN-A® Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: RETIN-A® (Tretinoin) Cream (Valeant)
Study: NCT03427554
Drug: Vehicle of the test product
Normalized name: The Magic Bullet Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
Study: NCT00214825
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg daily for 6 weeks with placebo
Study: NCT02407054
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02407054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02228395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in treatment arm
Study: NCT00312481
Drug: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
Normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
Study: NCT01005303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tablet Daily
Study: NCT02741557
Drug: DTG/RPV FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
Study: NCT01403285
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
Study: NCT01294644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT01106807
Drug: CD07223
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
Study: NCT01106807
Drug: Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microliters Epiduo Gel on one of the half-face for the morning dose
Study: NCT00234676
Drug: Premarin ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin ® 0.625 mg per day orally
Study: NCT01425398
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
Study: NCT01425398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
Study: NCT01319344
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg o.d. per os
Study: NCT00378976
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily as per experimental drug
Study: NCT03399903
Drug: Pentasa vs Align
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
Study: NCT00236171
Drug: Protopic, Advantan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00689624
Drug: Leukovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
Study: NCT01417052
Drug: 50 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: 100 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: 150 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: 200 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LX3305 once daily in capsule form
Study: NCT01315041
Drug: Inert alcoholic solution
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 drops, PO, 3 times a day, during 16 weeks
Study: NCT01417052
Drug: 250 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: 300 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: 400 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: 250 mg LX3305 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg LX3305 twice daily in capsule form
Study: NCT01417052
Drug: 500 mg LX3305 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg LX3305 once daily in capsule form
Study: NCT01417052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosing in capsule form
Study: NCT03617861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected once over one minute
Study: NCT02470858
Drug: LDV/SOF+ASV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
Study: NCT01087580
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week.
Study: NCT03503825
Drug: [Tc-99m]-RPI-T-087 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
Study: NCT01683162
Drug: Lipofundin
Approvals — FDA: no, EMA: no, PMDA: no
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study: NCT04533243
Drug: 2.5ug/h transdermal fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
Study: NCT03153267
Drug: Doxycycline 100 MG Oral Tablet bid, 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive doxycycline for 7 days.
Study: NCT03153267
Drug: Controls without a history of lyme disease.
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention.
Study: NCT04076423
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC / FTC / TAF
Study: NCT01570569
Drug: Cocktail
Normalized name: Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Study: NCT01570569
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Study: NCT04580563
Drug: OctaplasLG®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Study: NCT04511195
Drug: Diclofenac Sodium Gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
Study: NCT00882050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Study: NCT00421824
Drug: Oxaliplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
Study: NCT00421824
Drug: Oxaliplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
Study: NCT01131884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
Study: NCT02214914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03117894
Drug: Paracetamol 1,5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered preoperatively to prevent pain postoperatively.
Study: NCT03117894
Drug: Arcoxia, 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered preoperatively to prevent pain postoperatively.
Study: NCT02935582
Drug: Other topical
Normalized name: Other topical products for joint and muscular pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to local practise
Study: NCT00854919
Drug: atypical antipsychotic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
Study: NCT04580563
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Study: NCT00960349
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Study: NCT00193102
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine
Study: NCT01739972
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
Study: NCT01739972
Drug: Desiccated thyroid extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
Study: NCT02322450
Drug: QGC001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02322450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01733485
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/8 h for 5 days
Study: NCT01827878
Drug: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Study: NCT01433523
Drug: ALK HDM AIT Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lyophilisate, Placebo, to be administered sublingually once daily
Study: NCT03733561
Drug: LY03003
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
Study: NCT03733561
Drug: Neupro 4Mg/24Hr Transdermal Patch
Normalized name: Neupro 4mg/24hr Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: neupro patch
Study: NCT01617772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically looking placebo
Study: NCT02813356
Drug: non-PAMORA
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
Study: NCT04045821
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
Study: NCT04045821
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
Study: NCT02496767
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00170222
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03998163
Drug: CR845 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CR845 0.5 mcg/kg administered three times/week
Study: NCT01752153
Drug: Desferrioxamine, Legalon® (Silymarin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
Study: NCT01752153
Drug: Silymarin (Legalon)
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04305496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study: NCT03191097
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsules daily for 5 days.
Study: NCT02824536
Drug: 3BNC117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion of 3BNC117
Study: NCT02824536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Study: NCT03181503
Drug: CD14152 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Study: NCT03181503
Drug: CD14152 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Study: NCT03616444
Drug: Shenbai Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
Study: NCT00673725
Drug: Locobase® REPAIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: emollient
Study: NCT04658823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Softgel capsule containing soybean oil; 1 capsule twice daily
Study: NCT03879408
Drug: 440 mg naproxen sodium with 1000 mg acetaminophen
Normalized name: acetaminophen / naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
Study: NCT03879408
Drug: 220 mg naproxen sodium with 650 mg acetaminophen
Normalized name: naproxen sodium 220 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
Study: NCT03879408
Drug: 10 mg hydrocodone + 650 mg acetaminophen
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
Study: NCT03879408
Drug: 440 mg naproxen sodium
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
Study: NCT03879408
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of four placebo tablets
Study: NCT01490125
Drug: Placebo to QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
Study: NCT00598234
Drug: Celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
Study: NCT01676792
Drug: SR-T100 gel with 2.3% of SM in Solanum undatum plant extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
Study: NCT01779596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03235375
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0382 administered subcutaneously
Study: NCT02581124
Drug: JTZ-951
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01078519
Drug: Combined epidural and spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
Study: NCT03150498
Drug: BTD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTD-001 in fed vs fasted state
Study: NCT04189263
Drug: standard of care aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care aromatase inhibitors
Study: NCT00715182
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00213759
Drug: dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
Study: NCT01303744
Drug: CHF 5074 2x
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
Study: NCT01303744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, once a day in the morning for 12 weeks
Study: NCT01754389
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00997750
Drug: Lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam 8mg/day and 12mg/day for 15 days
Study: NCT01023841
Drug: Vehicle Sterile Solution
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Study: NCT03080116
Drug: ARN-509
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg/day (4x60mg tablets, Oral administration: OS)
Study: NCT00070018
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2
Study: NCT00070018
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2
Study: NCT02961062
Drug: SAF312
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02961062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03014713
Drug: Flubiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
Study: NCT03484221
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).